Similar findings were reported in a Chinese hereditary high-risk breast cancer cohort by Ni M et al, with the frequency of PALB2 pathogenic variants being 1.5% in HR+/HER2- breast cancer and 0.3% in TNBC (Ni et al. 2023). Here, ERBB2 is linked to breast carcinoma.